Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, Tarveda Therapeutics is raising $5,999,999.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brian Roberts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Tarveda Therapeutics
Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells. The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.

To learn more about Tarveda Therapeutics, visit http://www.tarveda.com/

Contact:
Brian Roberts, President and Chief Executive Officer
617-923-4100
https://www.linkedin.com/in/brian-roberts-77189a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved